AMAG buying once-bankrupt Lumara for up to $1bn
This article was originally published in Scrip
Executive Summary
AMAG Pharmaceuticals has been on the lookout for assets to add to its bag of marketed products for the past few years and now the company will pay up to $1bn to buy Lumara Health, formerly KV Pharmaceutical, which emerged from bankruptcy a year ago.
You may also be interested in...
AMAG's Makena Fails Confirmatory Pre-Term Birth Study, But May Not Be Pulled From Market
The company will conduct subgroup analyses to support ongoing use, but analysts believe Makena is unlikely to be pulled from the market when compounded progesterone is the only alternative therapy. Nevertheless, sales already are declining, since generics launched last year.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.